⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 1, 2024OncoTargets and TherapyOpen Access

Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs13181

Nadiya Nurul Afifah Lanny Indah Permatasari Ajeng Diantini Ruri Intania Indra Wijaya Hideru Obinata Melisa Intan Barliana

View Full Paper

Ask AI

Bookmark

Share

Abstract

Individual responses to platinum-based treatment for Non-Small Cell Lung Cancer (NSCLC) are influenced by genetic polymorphisms, including Single Nucleotide Polymorphisms (SNPs). This study aimed to explore the role of ERCC2 in the Nucleotide Excision Repair (NER) pathway for platinum-based chemotherapy in NSCLC. While

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Afifah et al. (2024) studied this question.

synapsesocial.com/papers/68e59fb2b6db64358753a4f5 https://doi.org/10.2147/ott.s475219

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer2024 · 6 citations
2Genetic signatures of <i>ERCC1</i> and <i>ERCC2</i> expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy2024 · 1 citations
3Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta‐Analysis2024 · 4 citations
4Association of POLR2E rs3787016 polymorphism with lung cancer risk and efficacy of platinum-based chemotherapy: A case–control study2025
5Lung cancer, predictive factor and ERCC12024